WCLC: Merck's Keytruda dispels 'urban legend' with latest lung cancer survival win

Merck’s Keytruda-chemo combo has a history of silencing its critics when it comes to its effectiveness in previously untreated NSCLC patients. And it may have just done it again. A pooled analysis from three trials showed that the combo majorly cut patients’ risk of death, even among those whose tumors tested negative for PD-L1.